Please login to the form below
Symdeko
This page shows the latest Symdeko news and features for those working in and with pharma, biotech and healthcare.
Vertex scores FDA approval for CF triple therapy Trikafta
and Symkevi/Symdeko (tezacaftor/ivacaftor) – which can treat around half of patients. ... The list price of $311, 000 is more than Leerink analyst Geoffrey Porges' prediction that the triple therapy could be priced similarly to Symdeko, which costs $233
Latest news
-
Leiden reassures on key role at Vertex
Kewalramani. The company's growth spurt is thanks to uptake of its new cystic fibrosis (CF) drugs, namely Symdeko/Symkevi, in the US and Germany.
-
Vertex files cystic fibrosis triple therapy with FDA
Leerink analyst Geoffrey Porges last year predicted that the triple therapy could be priced similarly to Symdeko, which costs $233, 000 for a year’s treatment in the US. ... However, independent US cost watchdog ICER concluded earlier this year that
-
Vertex eyes Duchenne market with Exonics, CRISPR deals
Its CF drugs Kalydeco, Orkambi and Symdeko/Symkevi collectively brought in $857m in sales in the first quarter of the year, up more than a third despite payer resistance in some
-
Setback for Vertex’s cystic fibrosis challenger Proteostasis
Vertex is running two parallel triplet studies, VX-659 Symdeko and VX-445 Symdeko, with one expected to emerge as superior, and be selected for filing. ... The data also included readouts from separate studies of PTI-801 and PTI-428 as add-on treatments
-
Vertex rises on data for cystic fibrosis triple therapy
The interim results come from two studies of its two-drug therapy Symdeko (ivacaftor/tezacaftor) – which has just been approved as Symkevi in Europe – with experimental candidate VX-659, and reveal ... that the regimen achieved a significant
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Vertex: a vision of treating all CF patients worldwide draws closer
Vertex is running two parallel triplet studies, VX- 659 Symdeko and VX-445 Symdeko, with one expected to emerge as superior, and be selected for filing.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- Sanofi halts recruitment for trials assessing MS treatment
- Eli Lilly to make bebtelovimab commercially available to US states from August
- The patient voice – the value of patient-reported outcomes in HTA
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- ONS records a continued fall in UK COVID-19 infections
- Powering Rapid Cognitive Analysis with AI
- How the Royal Society’s EiR programme can help to drive UK innovation
- BMS and 2seventy bio announce positive results for multiple myeloma treatment
- Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy
- Aqilion initiates phase 1 clinical trial for chronic inflammatory diseases
- JCVI publishes statement on London polio vaccination strategy
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris
- EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
- FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
